Clinical Evaluation of Eltrombopag in Chronic Idiopathic Thrombocytopenic Purpura (ITP)

Bio2RDF identifier

NCT00828750

http://www.w3.org/2001/XMLSchema#string

Bio2RDF namespace

clinicaltrials

http://www.w3.org/2001/XMLSchema#string

Bio2RDF uri

http://bio2rdf.org/clinicaltrials:NCT00828750

http://www.w3.org/2001/XMLSchema#string

identifiers.org URI

NCT00828750

actual enrollment [clinicaltrials_vocabulary:actual-enrollment]

19

http://www.w3.org/2001/XMLSchema#integer

brief summary [clinicaltrials_vocabulary:brief-summary]

An open-label, dose-adj ...... rial TRA108109 (NCT00540423).

http://www.w3.org/2001/XMLSchema#string

brief title [clinicaltrials_vocabulary:brief-title]

Clinical Evaluation of Eltrombopag in Chronic Idiopathic Thrombocytopenic Purpura (ITP)

http://www.w3.org/2001/XMLSchema#string

clinical result [clinicaltrials_vocabulary:clinical-result]

clinical results for clinicaltrials:NCT00828750 [clinicaltrials_resource:8654b54c29df0e578a751149faff1a2e]

clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]

Number of Participants Experiencing an Adverse Event (AE) and/or Serious Adverse Event (SAE) Within the Indicated Category From Baseline (Day 1) to last dose of eltrombopag/early withdrawal visit (up to 981 days) [clinicaltrials_resource:f01212c5704d07db5285f7265c847ea9]

clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]

Number of Participants Experiencing an Adverse Event (AE) and/or Serious Adverse Event (SAE) Within the Indicated Category From Baseline (Day 1) to last dose of eltrombopag/early withdrawal visit (up to 981 days) [clinicaltrials_resource:078ca5b405afdb0365d22b8306a4a550]

Number of Participants Experiencing an Adverse Event (AE) and/or Serious Adverse Event (SAE) Within the Indicated Category From Baseline (Day 1) to last dose of eltrombopag/early withdrawal visit (up to 981 days) [clinicaltrials_resource:84a10fe80cb18aefbb439a08b6f0520b]

Number of Participants Experiencing an Adverse Event (AE) and/or Serious Adverse Event (SAE) Within the Indicated Category From Baseline (Day 1) to last dose of eltrombopag/early withdrawal visit (up to 981 days) [clinicaltrials_resource:84cdaa243644fc3fdbeeb91de4048b31]

Number of Participants Experiencing an Adverse Event (AE) and/or Serious Adverse Event (SAE) Within the Indicated Category From Baseline (Day 1) to last dose of eltrombopag/early withdrawal visit (up to 981 days) [clinicaltrials_resource:8c716d366c2cc628915ed0cd8517a8fc]

Number of Participants Experiencing an Adverse Event (AE) and/or Serious Adverse Event (SAE) Within the Indicated Category From Baseline (Day 1) to last dose of eltrombopag/early withdrawal visit (up to 981 days) [clinicaltrials_resource:8d4cccf84b231a04b0f4b91abd0d6aa9]

Number of Participants Experiencing an Adverse Event (AE) and/or Serious Adverse Event (SAE) Within the Indicated Category From Baseline (Day 1) to last dose of eltrombopag/early withdrawal visit (up to 981 days) [clinicaltrials_resource:c5f501dfd6a62fe8cdcfc9bd2c788fdc]

Number of Participants Experiencing an Adverse Event (AE) and/or Serious Adverse Event (SAE) Within the Indicated Category From Baseline (Day 1) to last dose of eltrombopag/early withdrawal visit (up to 981 days) [clinicaltrials_resource:fcfdd586f8aa3c431232be423cb5ffda]

completion date [clinicaltrials_vocabulary:completion-date]

2011-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

condition [clinicaltrials_vocabulary:condition]

Purpura, Thrombocytopenic, Idiopathic [clinicaltrials_resource:8fd5b4539415edc1fbd6361e107cbbef]

Idiopathic Thrombocytopenic Purpura [clinicaltrials_resource:a50e60d877cf934fe788451681bb1706]

condition browse [clinicaltrials_vocabulary:condition-browse]

Purpura [clinicaltrials_resource:054b9b0e8b7aed8d0ae870ea3cb8366a]

Purpura, Thrombocytopenic [clinicaltrials_resource:47b789dd29778c11bc5545be874ae285]

Purpura, Thrombocytopenic, Idiopathic [clinicaltrials_resource:8fd5b4539415edc1fbd6361e107cbbef]

condition mesh [clinicaltrials_vocabulary:condition-mesh]

Purpura [clinicaltrials_resource:054b9b0e8b7aed8d0ae870ea3cb8366a]

Purpura, Thrombocytopenic [clinicaltrials_resource:47b789dd29778c11bc5545be874ae285]

Purpura, Thrombocytopenic, Idiopathic [clinicaltrials_resource:8fd5b4539415edc1fbd6361e107cbbef]

country [clinicaltrials_vocabulary:country]

Japan [clinicaltrials_resource:53a577bb3bc587b0c28ab808390f1c9b]

download date [clinicaltrials_vocabulary:download-date]

ClinicalTrials.gov processed this data on August 10, 2015

http://www.w3.org/2001/XMLSchema#string

eligibility [clinicaltrials_vocabulary:eligibility]

eligibility for clinicaltrials:NCT00828750 [clinicaltrials_resource:beb4e829181f7c6c18777b020ac30222]

firstreceived date [clinicaltrials_vocabulary:firstreceived-date]

2009-01-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

firstreceived results date [clinicaltrials_vocabulary:firstreceived-results-date]

2011-09-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

has expanded access [clinicaltrials_vocabulary:has-expanded-access]

No

http://www.w3.org/2001/XMLSchema#string

intervention [clinicaltrials_vocabulary:intervention]

Eltrombopag oral tablets [clinicaltrials_resource:1ba43d8944b529ea036321f98f3cfde1]

is fda regulated [clinicaltrials_vocabulary:is-fda-regulated]

No

http://www.w3.org/2001/XMLSchema#string

keyword [clinicaltrials_vocabulary:keyword]

ITP

http://www.w3.org/2001/XMLSchema#string

blood platelet

http://www.w3.org/2001/XMLSchema#string

eltrombopag

http://www.w3.org/2001/XMLSchema#string

thrombopoietin receptor agonist

http://www.w3.org/2001/XMLSchema#string

lastchanged date [clinicaltrials_vocabulary:lastchanged-date]

2011-10-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

lead sponsor [clinicaltrials_vocabulary:lead-sponsor]

GlaxoSmithKline [clinicaltrials_resource:8075d9d563cbe75004e7b6c2c4360b29]

location [clinicaltrials_vocabulary:location]

GSK Investigational Site [clinicaltrials_resource:cd7631da78aa528a30ef1d3f433da13f]

nct id [clinicaltrials_vocabulary:nct-id]

NCT00828750

http://www.w3.org/2001/XMLSchema#string

number of arms [clinicaltrials_vocabulary:number-of-arms]

1

http://www.w3.org/2001/XMLSchema#integer

official title [clinicaltrials_vocabulary:official-title]

Clinical Evaluation of Eltromb ...... NCT00540423)-<Phase III Study>

http://www.w3.org/2001/XMLSchema#string

org study id [clinicaltrials_vocabulary:org-study-id]

111,433

http://www.w3.org/2001/XMLSchema#integer

outcome [clinicaltrials_vocabulary:outcome]

Number of Participants Experiencing an Adverse Event (AE) and/or Serious Adverse Event (SAE) Within the Indicated Category [clinicaltrials_resource:NCT00828750/outcome/1]

overall official [clinicaltrials_vocabulary:overall-official]

GSK Clinical Trials [clinicaltrials_resource:482ca15ed5613e7d70d0185ac9204ca5]

overall status [clinicaltrials_vocabulary:overall-status]

Completed [clinicaltrials_resource:07ca5050e697392c9ed47e6453f1453f]

oversight [clinicaltrials_vocabulary:oversight]

Japan: Ministry of Health, Labor and Welfare [clinicaltrials_resource:c09e75ec0404e5c904b7b6444f4704ae]

participant flow [clinicaltrials_vocabulary:participant-flow]

participant flow for clinicaltrials:NCT00828750 [clinicaltrials_resource:0f63a78c3892a154b2fa0a1d7b99ba01]

phase [clinicaltrials_vocabulary:phase]

Phase 3 [clinicaltrials_resource:8357418e2694434468870b487644532d]

primary completion date [clinicaltrials_vocabulary:primary-completion-date]

2011-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

reported events [clinicaltrials_vocabulary:reported-events]

Reported events for NCT00828750 [clinicaltrials_resource:73d0a41d56f244592e0ab1e5b448826e]

responsible party [clinicaltrials_vocabulary:responsible-party]

Cheri Hudson; Clinical Disclosure Advisor, GSK Clinical Disclosure [clinicaltrials_resource:e036f8c95c19296a24aa3aa0e257aff1]

source [clinicaltrials_vocabulary:source]

GlaxoSmithKline [clinicaltrials_resource:8075d9d563cbe75004e7b6c2c4360b29]

start date [clinicaltrials_vocabulary:start-date]

2008-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

study design [clinicaltrials_vocabulary:study-design]

clinicaltrials:NCT00828750 study design [clinicaltrials_resource:fc84fca2560beff7aaabee9a45d83f64]

study type [clinicaltrials_vocabulary:study-type]

Interventional [clinicaltrials_resource:843ac00ae5d0b7c7defb84fb42c2ce31]

url [clinicaltrials_vocabulary:url]

NCT00828750

verification date [clinicaltrials_vocabulary:verification-date]

2011-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

identifier

clinicaltrials:NCT00828750

http://www.w3.org/2001/XMLSchema#string

title

Clinical Evaluation of Eltrombopag in Chronic Idiopathic Thrombocytopenic Purpura (ITP)

@en